Table 1 Baseline patient characteristics amongst all patients

Age, yr

58.0 ± 11

60 ± 2.3

57 ± 2.2

61.6 ± 2.0

0.41

Male Gender, n (%)

21,(61)

20,(77)

21,(68)

20,(61)

0.50

Body mass index, kg/m2

26 ± 2.9

27 ± 3.7

27 ± 4.0

30 ± 3.7

0.07

Hypertension, n (%)

18(56)

21(84)

119(61)

25(76))

0.08

Dyslipidemia, n (%)

8(25)

5(21)

19(61)

25(76)

0.63

Smoking, n (%)

15(76)

12(48)

15(48)

9(27)

0.23

Blood glucose, mmol/L

5.6 ± 1.1

6.2 ± 2.2

5.5 ± 1.0

7.6 ± 2.8

0.004

Triglycerides, mmol/L

1.7 ± 1.1

2.0 ± 0.3

2.0 ± 0.2

1.9 ± 0.2

0.63

Total cholesterol, mmol/L

4.4 ± 0.2

4.3 ± 0.2

4.4 ± 0.9

4.2 ± 0.2

0.92

Low-density lipoprotein, mmol/L

2.7 ± 0.9

2.7 ± 0.8

2.7 ± 0.3

2.5 ± 0.9

0.62

High-density lipoprotein, mmol/L

1.0 ± 0.04

1.0 ± 0.04

1.0 ± 0.03

0.98 ± 0.04

0.80

Hs CRP, mg/L, Median (Q1, Q3)

1.5(0.7,3.7)

0.64(0.4,1.6)

1.2(0.7,2.9)

1.4(0.7,6.5)

<0.001

Cr, μmol/L Median (Q1, Q3)

72(65,85)

76(67,86)

76(66,88)

77(63,84)

0.9

Ejection fraction, %

64 ± 5.7

63 ± 6.7

64 ± 7.3

62.2 ± 6.2

0.8

LVEDD, mm

47 ± 4.9

50.1 ± 4.5

48 ± 5.3

47 ± 4.6

0.20

BMP-2 (pg/mL)

17.1 ± 0.6

19.2 ± 0.3

18.7 ± 0.3

20.1 ± 0.3

P < 0.001

HbA1c (n %)

5.9 ± 1.52

7.3 ± 1.6

5.8 ± 0.7

8.23 ± 1.6

P < 0.001

Medications on admission

Aspirin, No. (%)

24(71)

18(69)

24(77)

26(78)

0.78

Clopidogrel, No. (%)

13(38)

12(46)

16(52)

20(61)

0.32

Beta-blockers, No. (%)

14(41)

12(48)

14(45)

16(48)

0.93

ACEI/ARB, No. (%)

14(42)

17(71)

16(76)

23(85)

0.0017

Statins, No. (%)

8(23.5)

15(58)

15(48)

22(67)

0.0025

Insulin, No. (%)

0(0)

17(65)

0(0)

23(79)

<0.001

Oral hypoglycemics, No. (%)

0(0)

18(69)

0(0)

25(86)

<0.001